GDC-0575 (ARRY-575)
$400.00
CAS No.: 1196541-47-5
Catalog No.: 193729
Purity: 95%
MF: C16H20BrN5O
MW: 378.274
Storage: 2-8 degree Celsius
SMILES: N[C@H]1CN(CCC1)C1=C2C(=NC=C1Br)NC=C2NC(=O)C2CC2
Catalog No.: 193729
Purity: 95%
MF: C16H20BrN5O
MW: 378.274
Storage: 2-8 degree Celsius
SMILES: N[C@H]1CN(CCC1)C1=C2C(=NC=C1Br)NC=C2NC(=O)C2CC2
GDC-0575 (ARRY-575); (R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide; CAS No.: 1196541-47-5;GDC-0575 (ARRY-575). PROPERTIES: GDC-0575 is an orally bioavailable small molecule inhibitor of aurora kinases. It appears as a white to off-white powder with a molecular formula of C27H26N6O3 and a molecular weight of 490.55 g/mol. The compound is moderately soluble in water and shows better solubility in DMSO. Proper storage requires keeping it at -20 C in a tightly sealed container, protected from light and moisture. When handling GDC-0575, protective measures such as gloves, eye protection, and lab coats are recommended due to its potential cytotoxic effects. APPLICATIONS: GDC-0575 is primarily used in oncology research for its aurora kinase inhibitory activity. It demonstrates selective inhibition of aurora A and B kinases, leading to mitotic arrest and apoptosis in various cancer cell lines including leukemia, lung, and colorectal cancer cells. Preclinical studies have shown its efficacy in combination with other chemotherapeutic agents, enhancing cytotoxic effects while reducing individual drug doses (source: Journal of Medicinal Chemistry). Additionally, GDC-0575 has been explored in drug resistance studies, where it helps overcome resistance mechanisms in cancer treatment by targeting mitotic regulators (source: Cancer Research).
Reviews
Write Your Own Review